Reactor production of Thorium-229

doi:10.1016/j.apradiso.2016.05.002

Title: Reactor production of Thorium-229

Full Record
Other Related Research

Abstract

Limited availability of ²²⁹Th for clinical applications of ²¹³Bi necessitates investigation of alternative production routes. In reactor production, ²²⁹Th is produced from neutron transmutation of ²²⁶Ra, ²²⁸Ra, ²²⁷Ac and ²²⁸Th. Here, we evaluate irradiations of ²²⁶Ra, ²²⁸Ra, and ²²⁷Ac targets at the ORNL High Flux Isotope Reactor.

Authors:

Boll, Rose Ann ^[1]; Murphy, Karen E. ^[1]; Denton, David L. ^[1]; Tamara J. Haverlock; Garland, Marc A. ^[1]; Mirzadeh, Saed ^[1]; Hogle, Susan ^[1]; Owens, Allison ^[1]

Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)

Publication Date:: 2016-05-03

Research Org.:: Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)

Sponsoring Org.:: USDOE Office of Nuclear Energy (NE)

OSTI Identifier:: 1253240

Alternate Identifier(s):: OSTI ID: 1358796

Grant/Contract Number:: AC05-00OR22725

Resource Type:: Accepted Manuscript

Journal Name:: Applied Radiation and Isotopes

Additional Journal Information:: Journal Volume: 114; Journal Issue: C; Journal ID: ISSN 0969-8043

Publisher:: Elsevier

Country of Publication:: United States

Language:: English

Subject:: 22 GENERAL STUDIES OF NUCLEAR REACTORS; Thorium-229; Thorium-228; Actinium-225; Actinium-227; Radium-226; Radium-228; neutron reactions; isochain; high flux isotope reactor

Citation Formats


                    Boll, Rose Ann, Murphy, Karen E., Denton, David L., Tamara J. Haverlock, Garland, Marc A., Mirzadeh, Saed, Hogle, Susan, and Owens, Allison. Reactor production of Thorium-229.  United States: N. p., 2016. 
        Web.  doi:10.1016/j.apradiso.2016.05.002.

Copy to clipboard


                    Boll, Rose Ann, Murphy, Karen E., Denton, David L., Tamara J. Haverlock, Garland, Marc A., Mirzadeh, Saed, Hogle, Susan, & Owens, Allison. Reactor production of Thorium-229.  United States.  doi:10.1016/j.apradiso.2016.05.002.

Copy to clipboard


                    Boll, Rose Ann, Murphy, Karen E., Denton, David L., Tamara J. Haverlock, Garland, Marc A., Mirzadeh, Saed, Hogle, Susan, and Owens, Allison. Tue .  
        "Reactor production of Thorium-229".  United States.  doi:10.1016/j.apradiso.2016.05.002.  https://www.osti.gov/servlets/purl/1253240.

Copy to clipboard


                    
@article{osti_1253240,

  title        = {Reactor production of Thorium-229},

  author       = {Boll, Rose Ann and Murphy, Karen E. and Denton, David L. and Tamara J. Haverlock and Garland, Marc A. and Mirzadeh, Saed and Hogle, Susan and Owens, Allison},

  abstractNote = {Limited availability of 229Th for clinical applications of 213Bi necessitates investigation of alternative production routes. In reactor production, 229Th is produced from neutron transmutation of 226Ra, 228Ra, 227Ac and 228Th. Here, we evaluate irradiations of 226Ra, 228Ra, and 227Ac targets at the ORNL High Flux Isotope Reactor.},

  doi          = {10.1016/j.apradiso.2016.05.002},

  journal      = {Applied Radiation and Isotopes},

  number       = C,

  volume       = 114,

  place        = {United States},

  year         = {2016},

  month        = {5}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Accepted Manuscript (Publisher)

Accepted Manuscript (DOE)

Publisher's Version of Record

DOI: 10.1016/j.apradiso.2016.05.002

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 1 work

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

ORNL production of the experimental alpha emitters bismuth-213 and actinium-225 for medical applications

Journal Article Webb, O F ; Krichinsky, A M ; Yong, L K - Transactions of the American Nuclear Society

Due to their short range in tissue (50 to 80 {micro}m), alpha emitters are of considerable interest for certain radioimmunotherapy applications. These applications require the destruction of single cells or small clusters of cells. The radioisotope {sup 213}Bi, which is milked from {sup 225}Ac, is an alpha emitter that is currently being used in phase-1 human leukemia trials at the Memorial Sloan-Kettering Cancer Center. The most readily achievable route for producing {sup 225}Ac generators involves separating ingrown {sup 229}Th daughters from the {sup 233}U parent. Thorium-229 is then used as a parent generator for {sup 225}Ac. Thorium-229 is easier tomore »« less
The application of poorly crystalline silicotitanate in production of ²²⁵Ac

Journal Article Fitzsimmons, Jonathan ; Abraham, Alyson ; Catalano, Demetra ; ... - Scientific Reports

Actinium-225 (²²⁵Ac) can be produced from a Thorium-229/Radium-225 (²²⁹Th/²²⁵Ra) generator, from high/low energy proton irradiated natural Thorium or Radium-226 target. Titanium based ion exchanger were evaluated for purification of ²²⁵Ac. Poorly crystalline silicotitanate (PCST) ion exchanger had high selectivity for Ba, Ag and Th. ²²⁵Ac was received with trace amounts of ²²⁷Ac, ²²⁷Th and ²²³Ra, and the solution was used to evaluate the retention of the isotopes on PCST ion exchanger. Over 90% of the ²²⁵Ac was recovered from PCST, and the radiopurity was >99% (calculated based on ²²⁵Ac, ²²⁷Th, and ²²³Ra). The capacity of the PCST inorganic ion exchangemore »« less
DOI: 10.1038/s41598-019-48021-7

Full Text Available
Measurement of cross sections for the {sup 232}Th(P,4n){sup 229}Pa reaction at low proton energies

Journal Article Jost, C. U. ; Griswold, J. R. ; Bruffey, S. H. ; ... - AIP Conference Proceedings

The alpha-emitters {sup 225}Ac and {sup 213}Bi are of great interest for alpha-radioimmunotherapy which uses radioisotopes attached to cancer-seeking antibodies to efficiently treat various types of cancers. Both radioisotopes are daughters of the long-lived {sup 229}Th(t{sub 1/2} = 7880y). {sup 229}Th can be produced by proton irradiation of {sup 232}Th and {sup 230}Th, either directly or through production of isobars that beta-decay into {sup 229}Th. To obtain excitation functions, {sup 232}Th and {sup 230}Th have been irradiated at the On-Line Test Facility at the Holifield Radioactive Ion Beam Facility at ORNL. Benchmark tests conducted with Cu and Ni foils showmore »« less
DOI: 10.1063/1.4802383
Production of Thorium-229 at the ORNL High Flux Isotope Reactor

Conference Boll, Rose Ann ; Garland, Marc A ; Mirzadeh, Saed

The investigation of targeted cancer therapy using -emitters has developed considerably in recent years and clinical trials have generated promising results. In particular, the initial clinical trials for treatment of acute myeloid leukemia have demonstrated the effectiveness of the -emitter 213Bi in killing cancer cells [1]. Pre-clinical studies have also shown the potential application of both 213Bi and its 225Ac parent radionuclide in a variety of cancer systems and targeted radiotherapy [2]. Bismuth-213 is obtained from a radionuclide generator system from decay of the 10-d 225Ac parent, a member of the 7340-y 229Th chain. Currently, 233U is the only viablemore »« less
Production of ${}^{229}{Th}$ for medical applications: Excitation functions of low-energy protons on ${}^{232}{Th}$ targets

Journal Article Griswold, Justin R. ; Jost, Carola U. ; Stracener, Daniel W. ; ... - Physical Review C

As a part of a general program to evaluate production routes for ²²⁹Th, we studied production of ²²⁹Th via proton-induced reactions on ²³²Th targets bombarded with low-energy protons, E_p ≤ 40MeV. The reported excitation functions include those for proton-induced reactions on natural thorium yielding to ^{228,229,230&232}Pa isotopes; ²³²Th(p,xn) reactions, where x=1, 3, 4, and 5, at proton energy ranges of 12–40 MeV. Although the data for ²³²Th(p,n)²²⁸Pa, ²³²Th(p,3n)²³⁰Pa, and ²³²Th(p,5n)²³²Pa reactions were deduced by direct analysis of the thorium foils after irradiation, the data for ²³²Th(p,4n)²²⁹Pa were obtained by radiochemical techniques. The half-life of ²²⁹Pa was evaluated and determined tomore »« less
DOI: 10.1103/PhysRevC.98.044607

Full Text Available

Similar Records